{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+in+Human&page=45",
    "query": {
      "condition": "First in Human",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 1234,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+in+Human&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+in+Human&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:36:50.879Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07165132",
      "title": "Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "GEP-NET",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "Gastroenteropancreatic Neuroendocrine Tumor Disease",
        "Neuroendocrine Tumors",
        "Carcinoid",
        "Carcinoid Tumor",
        "Pancreatic NET",
        "Solid Tumor",
        "Somatostatin Receptor"
      ],
      "interventions": [
        {
          "name": "RYZ401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RayzeBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2025-12-03",
      "completion_date": "2033-04",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07165132"
    },
    {
      "nct_id": "NCT02715011",
      "title": "Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "JNJ-63709178",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2016-06-01",
      "completion_date": "2021-03-26",
      "has_results": false,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 7,
      "location_summary": "Detroit, Michigan • New York, New York • Charlotte, North Carolina + 4 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715011"
    },
    {
      "nct_id": "NCT05245006",
      "title": "PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "89Zr-DFO-YS5",
          "type": "DRUG"
        },
        {
          "name": "YS5 antibody",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography (PET)/Computerized tomography (CT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Robert Flavell, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-03-18",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05245006"
    },
    {
      "nct_id": "NCT02254369",
      "title": "Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "GC021109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GliaCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2014-09",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-02-18",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 1,
      "location_summary": "Neptune City, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02254369"
    },
    {
      "nct_id": "NCT04808453",
      "title": "Phase I Study of CPI-300 in Patients With Advanced Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Tumors"
      ],
      "interventions": [
        {
          "name": "CPI-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coordination Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2021-06-15",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Lake Mary, Florida • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04808453"
    },
    {
      "nct_id": "NCT03369223",
      "title": "A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-986249",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2017-12-06",
      "completion_date": "2024-11-07",
      "has_results": true,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 19,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03369223"
    },
    {
      "nct_id": "NCT03199586",
      "title": "Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Pancreas Cancer",
        "Prostate Cancer",
        "Lung Cancer",
        "Colon Cancer",
        "Esophagus Cancer",
        "Liver Cancer",
        "Ovary Cancer",
        "Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies"
      ],
      "interventions": [
        {
          "name": "NP-G2-044",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novita Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-12-21",
      "completion_date": "2020-05-07",
      "has_results": false,
      "last_update_posted_date": "2025-07-20",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Duarte, California • New York, New York",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199586"
    },
    {
      "nct_id": "NCT05584670",
      "title": "A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "SAR445877",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "ADG126",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 542,
      "start_date": "2022-11-29",
      "completion_date": "2028-06-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 9,
      "location_summary": "Newark, Delaware • Iowa City, Iowa • Westwood, Kansas + 6 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05584670"
    },
    {
      "nct_id": "NCT05628961",
      "title": "Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Toxicity;Chemical"
      ],
      "interventions": [
        {
          "name": "HOPO 14-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SRI International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 42,
      "start_date": "2023-03-15",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 1,
      "location_summary": "Plymouth, Michigan",
      "locations": [
        {
          "city": "Plymouth",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05628961"
    },
    {
      "nct_id": "NCT05514496",
      "title": "A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "EGFR Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "NX-019",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nalo Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2022-10-05",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-11-19T05:36:50.879Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514496"
    }
  ]
}